| Literature DB >> 30539239 |
Rik Adrichem1, Saskia Le Cessie2,3, Mark G Hazekamp4, Nicolette A M Van Dam5, Nico A Blom1, Lukas A J Rammeloo6, Luc H P M Filippini7, Irene M Kuipers8, Arend D J Ten Harkel1, Arno A W Roest9.
Abstract
Pericardial effusion (PE) after pediatric cardiac surgery is common. Because of the lack of a uniform classification of the presence and severity of PE, we evaluated PE altering clinical management: clinically relevant PE. Risk factors for clinically relevant PE were studied. After cardiac surgery, children were followed until 1 month after surgery. Preoperative variables were studied in the complete cohort. Perioperative and postoperative variables were studied in a case-control manner. Patients with and without clinically relevant PE were matched on age, gender, and diagnosis severity in a 1:1 ratio. Multivariate analysis was conducted using important preoperative variables from the complete cohort combined with perioperative and postoperative variables from the case-control data. 1241 surgical episodes in 1031 patients were included. Clinically relevant PE developed in 136 episodes (11.0%). Multivariate correlation with the outcome was present for age, BSA (adjusted odds ratio: 1.6, 95% CI 0.9-2.8), right-sided heart defect (adjusted odds ratio: 1.3, 95% CI 0.9-1.9), history of previous operation (adjusted odds ratio: 0.5, 95% CI 0.3-0.7), cardiopulmonary bypass use (adjusted odds ratio: 2.1, 95% CI 0.9-4.5), duration of CPAP postoperatively, and an inotropic score (adjusted odds ratio: 1.01, 95% CI 0.998-1.03). In this large patient cohort, 11.0% of postoperative periods of pediatric cardiac surgery were complicated by PE requiring alteration of treatment. Secondly, we newly identified cardiopulmonary bypass use and right-sided heart defects as risk factors for clinically relevant PE and confirmed previously described risk factors: age, CPAP duration, BSA, and inotropic score and a previously described risk reductor: history of previous operation.Entities:
Keywords: Congenital heart disease; Pediatric cardiac surgery; Postoperative pericardial effusion; Risk assessment
Mesh:
Year: 2018 PMID: 30539239 PMCID: PMC6420454 DOI: 10.1007/s00246-018-2031-4
Source DB: PubMed Journal: Pediatr Cardiol ISSN: 0172-0643 Impact factor: 1.655
Comparison of peri- and postoperative characteristics between episodes with and without crPE
| CrPE ( | No crPE (135)b | Univariate odds ratio (95% CI) | Multivariate odds ratio (95% CI) | |||||
|---|---|---|---|---|---|---|---|---|
| % or IQR | % or IQR | Effect measure | 95% CI | Effect measure | 95% CI | |||
| Perioperative variables | ||||||||
| CPB use | 124 | 91.2% | 103 | 76.3% | 3.4 | 1.6–7.3 | 2.1 | 0.9–4.5 |
| Bypass duration | 94 min | 58–150 min | 74 min | 0.0–111.0 min | 1.006 | 1.002–1.011 | ||
| Clamp time | 59.0 min | 29.0–97.0 min | 42.0 min | 0.0–78.0 min | 1.008 | 1.003–1.013 | ||
| Postoperative variables | ||||||||
| Inotropic score | 12.0 | 4.8–21.0 | 8.00 | 1.0–15.0 | 1.02 | 0.998–1.033 | 1.01 | 0.998–1.03 |
| Total corticosteroid use | 65 | 47.8% | 57 | 42.2% | 1.4 | 0.79–2.6 | ||
| Anticoagulants use | 27 | 19.9% | 32 | 23.7% | 0.79 | 0.44–1.4 | ||
| Diuretics use | 111 | 81.6% | 110 | 81.4% | 1.00 | 0.51–2.0 | ||
| Antihypertensives use | 10 | 7.4% | 12 | 8.9% | 0.82 | 0.34–2.0 | ||
| NSAIDs use | 18 | 13.3% | 16 | 11.9% | 1.1 | 0.45–2.7 | ||
| Drain production | ||||||||
| 0–100 mL | 41 | 41.0% | 59 | 59.0% | 1 | |||
| 100–200 mL | 36 | 52.9% | 32 | 47.1% | 2.2 | 1.0–4.7 | ||
| 200–500 mL | 42 | 56.0% | 33 | 44.0% | 2.3 | 1.1–4.9 | ||
| > 500 mL | 17 | 60.7% | 11 | 39.3% | 3.1 | 1.1–8.6 | ||
| PRISM III score | 3.0 | 1.0–4.0 | 3.0 | 1.0–3.0 | 1.1 | 0.94–1.2 | ||
| PIM2 score | − 3.688 | − 4.019 to − 3.295 | − 3.710 | − 4.318 to − 3.378 | 1.2 | 0.92–1.7 | ||
| BiPAP/ASB duration | ||||||||
| 0–1 h | 19 | 61.2% | 12 | 38.8% | 1 | |||
| 1–12 h | 50 | 47.6% | 55 | 52.3% | 0.57 | 0.26–1.2 | ||
| 12–24 h | 21 | 55.3% | 17 | 44.7% | 0.82 | 0.31–2.1 | ||
| > 24 h | 46 | 47.4% | 51 | 52.6% | 0.53 | 0.21–1.3 | ||
| CPAP duration | ||||||||
| None | 69 | 41.3% | 98 | 58.7% | 1 | 1.0 | ||
| 0–1 h | 24 | 47.1% | 27 | 52.9% | 1.8 | 0.84–3.9 | 1.5 | 0.7–2.9 |
| 1–12 h | 22 | 84.6% | 4 | 15.4% | 16.3 | 3.4–77.4 | 10.8 | 3.3–35.2 |
| > 12 h | 21 | 77.8% | 6 | 22.2% | 8.9 | 2.4–33.9 | 4.4 | 1.5–12.8 |
| ICU duration | ||||||||
| ≤ 1 days | 50 | 47.2% | 54 | 52.8% | 1 | |||
| 1–5 days | 48 | 49.5% | 49 | 50.5% | 1.1 | 0.63–2.0 | ||
| 5–10 days | 22 | 56.4% | 17 | 43.6% | 1.5 | 0.69–3.4 | ||
| > 10 days | 16 | 51.6% | 15 | 48.4% | 1.3 | 0.54–2.9 | ||
| High urea | 33 | 24.3% | 31 | 23.0% | 1.1 | 0.63–2.0 | ||
| High creatinine | 11 | 8.1% | 12 | 8.9% | 1.1 | 0.35–3.3 | ||
ASB assisted spontaneous breathing, BiPAP bilevel positive airway pressure, CPAP continuous positive airway pressure, CPB cardiopulmonary bypass, crPE clinically relevant pericardial effusion, ICU intensive care unit, IQR interquartile range, NSAIDs non-steroidal anti-inflammatory drugs
aMissing values: bypass duration, n = 2; clamp time, n = 5; inotropic score, n = 1; total corticosteroid use, n = 1; anticoagulants use, n = 1; NSAIDs use, n = 1; drain production, n = 2; PRISM III, n = 8; PIM 2, n = 8; BiPAP ASB duration, n = 2; highest urea, n = 4; highest creatinine, n = 4. Total patients with ≥ 1 missing value(s), n = 17
Missing values: CPB use, n = 1; bypass duration, n = 23; clamp time, n = 2, PRISM III, n = 10; PIM 2, n = 10; IC duration, n = 5; highest urea, n = 8; highest creatinine, n = 8. Total patients with ≥ 1 missing value(s), n = 33
Fig. 1Flow chart of patient inclusion. CrPE clinically relevant pericardial effusion
Patient characteristics at time of surgery in the included surgical episodes
| Variable | Total episodes ( | |
|---|---|---|
| % or IQR | ||
| Male | 696 | 56.1% |
| Age at operation | 8 months | 2–49 months |
| 0–1 month | 213 | 17.2% |
| 1–6 months | 365 | 29.4% |
| 6 months–1 year | 124 | 10.0% |
| 1–18 years | 539 | 43.4% |
| Length | 80 cm | 62.0–112.0 cm |
| Weight | 7.6 kg | 4.3–15.8 kg |
| BSA | 0.45 m2 | 0.30–0.73 m2 |
| Previous operation | 478 | 38.5% |
| Diagnosis severity | ||
| Simple | 197 | 15.9% |
| Moderate | 419 | 33.8% |
| Severe | 625 | 50.4% |
| Pericardial effusion | 301 | 24.3% |
| Clinically relevant | 136 | 11.0% |
BSA body surface area, IQR interquartile range
aMissing values: length, n = 259; weight, n = 10; BSA, n = 261. Total patients missing ≥ 1 values, n = 261
Comparison of preoperative characteristics between episodes with and without crPE
| Variable | CrPE ( | No crPE (1105)b | Univariate odds ratio (95% CI) | Multivariate odds ratio (95% CI) | ||||
|---|---|---|---|---|---|---|---|---|
| % or IQR | % or IQR | Effect measure | 95% CI | Effect measure | 95% CI | |||
| Male | 70 | 51.5% | 627 | 56.7% | 1.2 | 0.9–1.8 | ||
| Age at operation | 15 months | 4–85 months | 7 months | 1–46 months | 1.004 | 1.002–1.007 | ||
| 0–1 month | 9 | 4.2% | 204 | 95.8% | 1 | 1.0 | ||
| 1–6 months | 35 | 9.6% | 329 | 90.4% | 2.4 | 1.1–5.1 | 2.2 | 1.0–4.8 |
| 6 months–1 year | 20 | 16.1% | 104 | 83.9% | 4.4 | 1.9–9.9 | 4.1 | 1.7–9.9 |
| 1–18 years | 72 | 13.3% | 468 | 86.7% | 3.5 | 1.7–7.1 | 3.1 | 1.3–7.2 |
| Length | 86 cm | 67–124 cm | 80 cm | 62–109 cm | 1.008 | 1.003–1.013 | ||
| Weight | 9.45 kg | 5.3–24.25 kg | 7.5 kg | 4.0–15.0 kg | 1.015 | 1.005–1.025 | ||
| BSA | 0.48 m2 | 0.32–0.94 m2 | 0.43 m2 | 0.29–0.71 m2 | 1.85 | 1.27–2.71 | 1.6 | 0.9–2.8 |
| Previous operation | 39 | 28.7% | 439 | 39.7% | 0.6 | 0.4–0.9 | 0.5 | 0.3–0.7 |
| Diagnosis severity | ||||||||
| Simple | 26 | 13.2% | 171 | 86.8% | 1 | |||
| Moderate | 52 | 12.4% | 368 | 87.6% | 0.9 | 0.6–1.5 | ||
| Severe | 58 | 9.3% | 566 | 90.7% | 0.7 | 0.4–1.1 | ||
| Right-sided heart defect | 53 | 39.0% | 322 | 29.1% | 1.6 | 1.1–2.2 | 1.3 | 0.9–1.9 |
BSA body surface area, crPE clinically relevant pericardial effusion, IQR interquartile range
aMissing values: length, n = 15; weight, n = 2; BSA, n = 15. Total patients with ≥ 1 missing value(s), n = 15
bMissing values: length, n = 244; weight, n = 8; BSA, n = 246. Total patients with ≥ 1 missing value(s), n = 246
Characteristics of specific subgroups of episodes in which crPE developed
| Variable | CrPE development after discharge ( | Episodes requiring pericardial drainage ( | ||
|---|---|---|---|---|
|
| % |
| % | |
| Male (%) | 13 | 50.0 | 19 | 59.4 |
| Age at operation | ||||
| < 3 years old | 12 | 46.2 | 22 | 68.8 |
| > 3 years old | 14 | 53.8 | 10 | 31.2 |
| Diagnosis severity | ||||
| Simple | 5 | 19.2 | 2 | 6.3 |
| Moderate | 13 | 50.0 | 9 | 28.1 |
| Severe | 8 | 30.8 | 20 | 65.6 |
| Initiated therapy | ||||
| Additional check-ups, | 9 | 34.6 | 1 | 3.1 |
| NSAIDs, | 2 | 7.7 | 2 | 6.3 |
| Diuretics, | 9 | 34.6 | 13 | 40.6 |
| Corticosteroids, | 4 | 15.4 | 9 | 28.1 |
| Pericardial drainage, | 7 | 26.9 | 32 | 100 |
crPE clinically relevant pericardial effusion, IQR interquartile range, NSAIDs non-steroidal anti-inflammatory drugs